{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Cancer+%28GC%29", "query": { "condition": "Gastroesophageal Cancer (GC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Cancer+%28GC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:32:23.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07217704", "title": "Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer (GC)", "Gastroesophageal Junction" ], "interventions": [ { "name": "[18F]FAPI-74 PET/CT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SOFIE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-11-14", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 10, "location_summary": "Cerritos, California • Irvine, California • Los Angeles, California + 7 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217704" }, { "nct_id": "NCT07419841", "title": "A Phase 1 Study of the Safety and Tolerability of CTX-10726", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroesophageal Cancer (GC)", "Hepatocellular Carcinoma (HCC)", "Endometrial Cancer", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "CTX-10726", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Compass Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2026-05-01", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 4, "location_summary": "Omaha, Nebraska • Lake Success, New York • Greenville, South Carolina + 1 more", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Lake Success", "state": "New York" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07419841" }, { "nct_id": "NCT07277413", "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Gastric Adenocarcinoma", "Adenocarcinoma of Esophagus", "Squamous Cell Car. - Esophagus", "Urothelial Carcinoma (UC)", "Bladder Cancer", "Mesothelioma", "Pleural Mesothelioma", "Peritoneal Mesothelioma", "Non-Small Cell Lung Cancer NSCLC" ], "interventions": [ { "name": "IDE892", "type": "DRUG" }, { "name": "IDE397", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-03-04", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 10, "location_summary": "Orlando, Florida • Omaha, Nebraska • New York, New York + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277413" }, { "nct_id": "NCT07069712", "title": "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "FLOT Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-07-17", "completion_date": "2028-09-06", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 7, "location_summary": "Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "North Shores", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07069712" }, { "nct_id": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 980, "start_date": "2025-08-12", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 15, "location_summary": "San Francisco, California • Hartford, Connecticut • New Haven, Connecticut + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070232" }, { "nct_id": "NCT03704077", "title": "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Cancer of the Stomach", "Stomach Cancer", "Gastroesophageal Junction" ], "interventions": [ { "name": "Relatlimab + Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-10-31", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2020-05-19", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 20, "location_summary": "Daphne, Alabama • Bakersfield, California • Fullerton, California + 17 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03704077" }, { "nct_id": "NCT05733689", "title": "Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "FLOT", "type": "COMBINATION_PRODUCT" }, { "name": "FOLFOX", "type": "COMBINATION_PRODUCT" }, { "name": "FOLFIRI", "type": "COMBINATION_PRODUCT" }, { "name": "FOLFIRINOX", "type": "COMBINATION_PRODUCT" }, { "name": "PACLITAXEL with or without CARBOPLATIN", "type": "COMBINATION_PRODUCT" }, { "name": "DOCETAXEL and IRINOTECAN (alone or combined)", "type": "COMBINATION_PRODUCT" }, { "name": "NIVOLUMAB (alone or when added to a regimen above)", "type": "DRUG" }, { "name": "PEMBROLIZUMAB (alone or when added to a regimen above)", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-06-27", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733689" }, { "nct_id": "NCT06157892", "title": "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Gastroesophageal Junction Adenocarcinoma", "HER2 Low Breast Neoplasms", "HER2 Positive Breast Neoplasms", "Stomach Neoplasms", "Triple Negative Breast Neoplasms", "Metastatic Breast Cancer", "Metastatic Gastric Cancer", "Advanced Breast Cancer", "Advanced Gastric Cancer" ], "interventions": [ { "name": "disitamab vedotin", "type": "DRUG" }, { "name": "tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2024-05-20", "completion_date": "2029-07-28", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 82, "location_summary": "Tucson, Arizona • Orange, California • San Francisco, California + 43 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06157892" }, { "nct_id": "NCT06131840", "title": "A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Stomach Neoplasms", "Pancreatic Ductal Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Small Cell Lung Carcinoma" ], "interventions": [ { "name": "PF-08046050", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin (LV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2023-11-20", "completion_date": "2030-09-12", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06131840" }, { "nct_id": "NCT04592913", "title": "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Neoplasms", "Esophagogastric Junction" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "FLOT chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "200 Years", "sex": "ALL", "summary": "18 Years to 200 Years" }, "enrollment_count": 957, "start_date": "2020-11-17", "completion_date": "2027-09-27", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-05-21T22:32:23.125Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Sylmar, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592913" } ] }